# US 2016/0355784 A1 · Methods, Kits, and Compositions for Stem Cell Self-Renewal

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0355784 A1
- Document ID: US20160355784A1
- Status: Published application
- Kind: A1
- Application number: 15/156,851
- Filed: 2016-05-17
- Published: 2016-12-08
- Earliest claimed: 2007-04-23
- Assignees: Stowers Institute for Medical Research
- Applicants: Stowers Institute for Medical Research
- Inventors: John M. Perry; Linheng Li; Justin C. Grindley
- Web page: https://patentgrep.com/patent/US20160355784A1

## CPC

- C12N 5/0647: {Haematopoietic stem cells; Uncommitted or multipotent progenitors}
- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 7/06: Antianaemics
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 2501/40: Regulators of development
- C12N 2501/415: Wnt; Frizzeled
- C12N 2501/70: Enzymes
- C12N 2502/11: blood or immune system cells
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to methods and kits for expanding a stem cell population. More particularly, the invention relates, inter alia, to methods, kits, and compositions for expanding a stem cell population, particularly a hematopoietic stem cell population.

## Claims

### Claim 1

An ex vivo method for expanding the number of hematopoietic stem cells (HSC) in a population of mononuclear cells (MNC) comprising culturing the population of MNCs comprising at least one HSC in an HSC expansion media for a period of time sufficient to expand the number of HSCs in the MNC population, wherein the expanded HSCs are functional with long term, multi-lineage, repopulating potential.

### Claim 2 (depends on 1)

The method according to claim 1, which provides HSCs that, upon transplant into a recipient, exhibit greater than 5% donor repopulation.

### Claim 3 (depends on 1)

The method according to claim 1, which provides HSCs that, upon transplant into a recipient, exhibit greater than 25% donor repopulation.

### Claim 4 (depends on 1)

The method according to claim 1, which provides HSCs that, upon transplant into a recipient, exhibit greater than 45% donor repopulation.

### Claim 5 (depends on 1)

The method according to claim 1, which provides HSCs that, upon transplant into a recipient, exhibit greater than 60% donor repopulation.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the HSC expansion media comprises a modulator of the Wnt pathway.

### Claim 7 (depends on 6)

The method according to claim 6, wherein the modulator of the Wnt pathway down-regulates GSK-3β.

### Claim 8 (depends on 6)

The method according to claim 6, wherein the modulator of the Wnt pathway is a reversible GSK-3β inhibitor selected from the group consisting of a small molecule, a biologic, an antisense RNA, a small interfering RNA (siRNA), and combinations thereof.

### Claim 9 (depends on 8)

The method according to claim 8, wherein the reversible GSK-3β inhibitor is a small molecule.

### Claim 10 (depends on 8)

The method according to claim 8, wherein the reversible GSK-3β inhibitor is selected from the group consisting of Hymenialdisine, Flavopiridol, Kenpaullone, Alsterpaullone, Azakenpaullone, Indirubin-30-oxime, 6-Bromoindirubin-30-oxime (BIO), 6-Bromoindirubin-30-acetoxime, Aloisine A, Aloisine B, TDZD8, Compound 12, CHIR98014, CHIR99021 (CT99021), CT20026, Compound 1, SU9516, ARA014418, Staurosporine, Compound 5a, Compound 29, Compound 46, GF109203x (bisindolylmaleimide I), Ro318220 (bisindolylmaleimide IX), SB216763, SB415286, I5, CGP60474, Compound 8b, TWS119, Compound 1A, Compound 17, Lithium, Beryllium, Zinc, small molecule GSK-3β inhibitors (Vertex Pharmaceuticals), NP-12 (Neuropharma), GSK-3β inhibitors (Amphora), GSK-3β inhibitors (CrystalGenomics), SAR-502250 (Sanofi-Aventis), 3544 (Hoffmann-La Roche), GSK-3β inhibitors (Lundbeck), TDZD-8 (Cancer Center, University of Rochester), pharmaceutically acceptable salts thereof, and combinations thereof.

### Claim 11 (depends on 10)

The method according to claim 10, wherein the GSK-3β inhibitor is CHIR99021.

### Claim 12 (depends on 6)

The method according to claim 6, which provides HSCs that, upon transplant into a recipient, exhibit greater than 60% donor repopulation.

### Claim 13 (depends on 1)

The method according to claim 1, wherein the HSC is obtained from a mammalian tissue selected from the group consisting of cord blood, peripheral blood, and bone marrow.

### Claim 14 (depends on 1)

An expanded, substantially undifferentiated HSC population made by the method according to claim 1.

### Claim 15 (depends on 6)

An expanded, substantially undifferentiated HSC population made by the method according to claim 6.

### Claim 16

A kit for expanding, ex vivo, the number of hematopoietic stem cells (HSC) in a population of mononuclear cells (MNC), the kit comprising a GSK-3β inhibitor, and instructions for the use of the inhibitor, wherein, when used, the kit provides expanded HSCs that are functional with long term, multi-lineage, repopulating potential.

### Claim 17 (depends on 16)

The kit according to claim 16, wherein the GSK-3β inhibitor is selected from the group consisting of Hymenialdisine, Flavopiridol, Kenpaullone, Alsterpaullone, Azakenpaullone, Indirubin-30-oxime, 6-Bromoindirubin-30-oxime (BIO), 6-Bromoindirubin-30-acetoxime, Aloisine A, Aloisine B, TDZD8, Compound 12, CHIR98014, CHIR99021 (CT99021), CT20026, Compound 1, SU9516, ARA014418, Staurosporine, Compound 5a, Compound 29, Compound 46, GF109203x (bisindolylmaleimide I), Ro318220 (bisindolylmaleimide IX), SB216763, SB415286, I5, CGP60474, Compound 8b, TWS119, Compound 1A, Compound 17, Lithium, Beryllium, Zinc, small molecule GSK-3β inhibitors (Vertex Pharmaceuticals), NP-12 (Neuropharma), GSK-3β inhibitors (Amphora), GSK-3β inhibitors (CrystalGenomics), SAR-502250 (Sanofi-Aventis), 3544 (Hoffmann-La Roche), GSK-3β inhibitors (Lundbeck), TDZD-8 (Cancer Center, University of Rochester), pharmaceutically acceptable salts thereof, and combinations thereof.

### Claim 18 (depends on 16)

The kit according to claim 16, wherein the GSK-3β inhibitor is CHIR99021.

### Claim 19 (depends on 16)

The kit according to claim 16, which provides HSCs that, upon transplant into a recipient, exhibit greater than 60% donor repopulation.

### Claim 20

A media for carrying out ex vivo expansion of a stem cell in a population of MNCs comprising a fluid media suitable for maintaining viable stem cells and a GSK-3β inhibitor present in the media at a concentration sufficient to enable expansion of the stem cell population while maintaining a long term, multi-lineage, repopulating potential in the stem cells, wherein the stem cells, when transplanted into a recipient, exhibit greater than 5% donor repopulation.

### Claim 21

An ex vivo method for expanding the number of cells capable of supporting multi-lineage repopulation in a population of mononuclear cells (MNC) comprising culturing the population of MNCs comprising at least one hematopoietic stem cell (HSC) and at least one hematopoietic progenitor cell in an HSC expansion media for a period of time sufficient to expand the number of cells capable of supporting multi-lineage repopulation in the MNC population.

### Claim 22 (depends on 10)

The method according to claim 10, wherein the GSK-3β inhibitor is lithium, a pharmaceutically acceptable salt thereof, or combinations thereof.

### Claim 23 (depends on 22)

An expanded, substantially undifferentiated HSC population made by the method according to claim 22.

### Claim 24 (depends on 16)

The kit according to claim 16, wherein the GSK-3β inhibitor is lithium, a pharmaceutically acceptable salt thereof, or combinations thereof.

### Claim 25 (depends on 20)

The media according to claim 20, wherein the GSK-3β inhibitor is lithium, a pharmaceutically acceptable salt thereof, or combinations thereof.

### Claim 26 (depends on 21)

The method according to claim 21, wherein the HSC expansion media comprises a reversible GSK-3β inhibitor.

### Claim 27 (depends on 26)

The method according to claim 26, wherein the reversible GSK-3β inhibitor is lithium, a pharmaceutically acceptable salt thereof, or combinations thereof.
